Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
fda
5
×
life sciences
national blog main
national top stories
new york blog main
5
×
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
bristol-myers squibb
cancer
drugs
eli lilly
immunotherapy
loxo oncology
merck
pfizer
regeneron pharmaceuticals
rna interference
roche
What
time
5
×
fda
approved
days
drug
friday
medicine
agency
ago
aimmune
airport
allergy
alliance
alnylam
annual
apocalypse
approval
approve
awaits
awarded
beds
bio
biological
bristol
buy
calls
cancer
celgene
changing
color
crispr
crossed
decades
decision
deeper
developed
discovered
dna
fallout
fingerprint
Language
unset
Current search:
time
×
fda
×
" new york blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision